WEBULL
WebtradeDownload

Virbac (ENXTPA:VIRP) Could Be 23% Undervalued After Board Changes

Simply Wall St · 1d ago

Virbac (ENXTPA:VIRP) has drawn fresh attention after appointing Eline Madelpuech as a non-voting board member and adding independent director Olivier Charmeil to its Audit Committee, prompting investors to revisit the stock’s governance profile.

Virbac’s latest governance refresh comes after a mixed price pattern. The €318.0 share price has seen a 2.09% 7-day return and a 10.04% decline year to date, while the 3-year total shareholder return of 20.85% signals steadier long-run momentum.

Scan how Virbac compares with other quality operators by jumping across to a hand-picked set of list of solid balance sheet and fundamentals (207 results).

Virbac now trades at €318.0, while both analyst targets and intrinsic estimates sit materially higher. The real question is how investors should treat that gap in the next valuation check.

Most Popular Narrative: 23% Undervalued

Virbac’s most followed narrative compares a fair value of €412.88 with the current €318.0 share price. This shifts the focus to what would need to go right in the business for that gap to close.

The construction of new facilities, including a new biology site in Carros, a pet food facility in Nîmes, and a logistics center in Carros, aims to enhance operational capacity and efficiency, potentially improving gross margins and profitability. Despite elevated inflation and personnel costs, Virbac is working on optimizing inventory management and improving gross margins through competitive programs at manufacturing sites, which could result in an improved net margin.

See why 7 investors see Virbac as 23% undervalued.

Result: Fair Value of €412.88 (UNDERVALUED)

Still, Virbac’s heavier R&D spend and higher net debt from acquisitions could pressure margins if new projects and deals do not deliver as planned.

Find out about the key risks to this Virbac narrative.

Next Steps

If the mix of optimism and caution around Virbac feels familiar, treat that tension as your cue to move quickly and test the numbers yourself. To see what is driving the positive angles in this story, review the 5 key rewards.

Looking for more Virbac investment ideas?

If Virbac has sharpened your appetite for opportunities with clear data behind them, do not stop here. Your next strong idea could be just one filter away.

  • Target resilient compounding potential by scanning a focused 226 resilient stocks with low risk scores that prioritises businesses with steadier risk profiles and more durable financial foundations.
  • Pursue value opportunities by working through a curated 618 high quality undiscovered gems that highlights companies with solid fundamentals that fewer investors are watching.
  • Build income-focused exposure by reviewing a hand picked 225 dividend fortresses aimed at stocks offering higher yields backed by robust financials.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.